Analyst Scoreboard: 5 Ratings For Vericel
Vericel (NASDAQ:VCEL) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Vericel and provided 12-month price targets. The average target is $51.6, accompanied by a high estimate of $54.00 and a low estimate of $46.00. This upward trend is evident, with the current average reflecting a 10.02% increase from the previous average price target of $46.90.
Deciphering Analyst Ratings: An In-Depth Analysis
An in-depth analysis of recent analyst actions unveils how financial experts perceive Vericel. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Samuel Brodovsky | Truist Securities | Maintains | Buy | $54.00 | $54.00 |
| Samuel Brodovsky | Truist Securities | Raises | Buy | $54.00 | $51.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $53.00 | $46.00 |
| Samuel Brodovsky | Truist Securities | Raises | Buy | $51.00 | $39.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $46.00 | $44.50 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Vericel. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vericel compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Vericel's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Capture valuable insights into Vericel's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Vericel analyst ratings.
Get to Know Vericel Better
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
A Deep Dive into Vericel's Financials
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Vericel's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 23.35%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vericel's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 19.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Vericel's ROE stands out, surpassing industry averages. With an impressive ROE of 6.04%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Vericel's ROA excels beyond industry benchmarks, reaching 3.87%. This signifies efficient management of assets and strong financial health.
Debt Management: Vericel's debt-to-equity ratio is below the industry average. With a ratio of 0.39, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.